151 related articles for article (PubMed ID: 26642701)
1. Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
Zhuang X; Sun F; Li L; Jiang D; Li X; Sun A; Pan Z; Lou N; Zhang L; Lou F
Clin Lab; 2015; 61(10):1409-14. PubMed ID: 26642701
[TBL] [Abstract][Full Text] [Related]
2. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus.
Zhang Z; Wang J; Wang H
Exp Ther Med; 2018 Mar; 15(3):2936-2940. PubMed ID: 29456698
[TBL] [Abstract][Full Text] [Related]
3. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
Farhangi MA; Alipour B; Jafarvand E; Khoshbaten M
Arch Med Res; 2014 Oct; 45(7):589-95. PubMed ID: 25450583
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
Hu H; Wang J; Li X; Shen L; Shi D; Meng J
Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
6. Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients.
Hu Y; Liu J; Dong X; Xu Y; Leng S; Wang G
Med Sci Monit; 2016 Nov; 22():4146-4151. PubMed ID: 27803497
[TBL] [Abstract][Full Text] [Related]
7. The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid.
Li YL; Xie H; Musha H; Xing Y; Mei CX; Wang HJ; Wulasihan M
Cell Biochem Biophys; 2015 Jul; 72(3):643-7. PubMed ID: 27352181
[TBL] [Abstract][Full Text] [Related]
8. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Panahi Y; Ghamarchehreh ME; Beiraghdar F; Zare R; Jalalian HR; Sahebkar A
Hepatogastroenterology; 2012 Oct; 59(119):2099-2103. PubMed ID: 23234816
[TBL] [Abstract][Full Text] [Related]
10. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
[TBL] [Abstract][Full Text] [Related]
11. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
[TBL] [Abstract][Full Text] [Related]
12. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
13. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients.
Yu S; Zhang Y; Li MZ; Xu H; Wang Q; Song J; Lin P; Zhang L; Liu Q; Huang QX; Wang K; Hou WK
Chin Med J (Engl); 2012 Oct; 125(19):3440-4. PubMed ID: 23044303
[TBL] [Abstract][Full Text] [Related]
14. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
Saad ZA; Khodeer DM; Zaitone SA; Ahmed AAM; Moustafa YM
Life Sci; 2020 Jul; 253():117725. PubMed ID: 32348835
[TBL] [Abstract][Full Text] [Related]
15. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Li JJ; Zhang P; Fan B; Guo XL; Zheng ZS
Rev Assoc Med Bras (1992); 2019 Jan; 65(1):33-37. PubMed ID: 30758417
[TBL] [Abstract][Full Text] [Related]
18. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?
Shargorodsky M; Omelchenko E; Matas Z; Boaz M; Gavish D
Cardiovasc Diabetol; 2012 Jun; 11():61. PubMed ID: 22676459
[TBL] [Abstract][Full Text] [Related]
19. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
[TBL] [Abstract][Full Text] [Related]
20. [Effect of metformin on the expression of SIRT1 and UCP2 in rat liver of type 2 diabetes mellitus and nonalcoholic fatty liver].
Xu J; Li N; Wang J; Zhang C; Ding S; Jiao Y; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):882-7. PubMed ID: 24071688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
